Kamicin

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kamicin

Property Description
Active ingredient Clotrimazol
Pharmacological class Azole Antifungal / Antimycotic
Forms Cream, Solution, Vaginal Tablet, Lozenge
General Purpose Treatment of Fungal Infections (Mycoses)
Origin Synthetic (Imidazole Derivative)

Kamicin is a specialized pharmaceutical preparation whose identity is fundamentally defined by its single active component, Clotrimazol (INN). It is formally classified as an antifungal agent (antimycotic), placing it within the therapeutic group of medicines specifically used against infections caused by fungi and yeasts. Clotrimazol is clinically recognized for its effectiveness across various types of superficial fungal outbreaks.

Clotrimazol is a synthetic compound belonging to the azole antifungal class, specifically categorized as an imidazole derivative. This indicates the medicine’s structure and its origin from a precise chemical synthesis, ensuring high purity and consistent potency. The drug is often positioned for patients requiring localized and non-systemic treatment for common mycoses. Clotrimazol is indicated for the local treatment of vulvovaginal candidosis.

To facilitate effective local treatment across various infected tissues, Kamicin is manufactured in several dosage forms tailored for topical and transmucosal delivery. These pharmaceutical preparations include a topical cream or solution for skin application, as well as solid forms such as vaginal tablets or lozenges for use on mucosal surfaces. The final product consists of the active Clotrimazol suspended within an appropriate base/vehicle to ensure reliable local delivery to the site of the mycosis, confirming its dedicated role in managing fungal outbreaks.

Regulatory References

  1. Clotrimazole Label Information - DailyMed
  2. WHO Model List of Essential Medicines
  3. Clotrimazole in WHO Essential Medicines List

What side effects are possible with Kamicin?

Kamicin (an aminoglycoside antibiotic) is generally reserved for serious infections where other antibiotics may be ineffective. Its use carries a risk of significant, potentially irreversible side effects, primarily affecting the kidneys and the inner ear.

Serious Side Effects and Warnings

Consult your healthcare provider immediately if you experience any of the following:

  • Ototoxicity (Ear Damage): Symptoms can include tinnitus (ringing or roaring in the ears), a sensation of vertigo or spinning, loss of balance, or any degree of hearing loss. These effects may be permanent and can progress even after treatment is stopped. Regular hearing tests may be necessary during therapy.
  • Nephrotoxicity (Kidney Damage): Signs of kidney issues include a change in the frequency or amount of urine, swelling in the hands, ankles, or feet, unusual weakness, or increased thirst. Kidney function is typically monitored with blood and urine tests before and during treatment.
  • Neuromuscular Blockade: In rare cases, this can lead to muscle twitching, severe muscle weakness, or difficulty breathing, which can progress to respiratory paralysis.
  • Severe Allergic Reaction (Anaphylaxis): Symptoms like swelling of the face, lips, tongue, or throat, hives, or trouble breathing require immediate medical attention.

Less Common Side Effects

More common, though typically less severe, side effects include nausea, vomiting, diarrhea, headache, fever, and pain or irritation at the injection site. If these symptoms are persistent or worsen, inform your doctor.

Safety Information

The risk of serious toxicity is increased in patients with pre-existing kidney problems, dehydration, advanced age, or those receiving high doses or prolonged treatment. Kamicin is not recommended during pregnancy, as it may cause fetal harm, including congenital deafness. Discuss your complete medical history and all current medications with your healthcare provider, as certain drugs can increase the risk of Kamicin's side effects.

Overdose and Emergency Response

Overdose and When to Seek Help

The overdose profile for Kamicin (Clotrimazol) in its topical and vaginal forms is defined by the regulatory classification of minimal systemic risk. Official government documents state that acute intoxication is unlikely to occur following a single dermal or vaginal application due to very low systemic absorption.

Overdose Manifestations and Required Actions

Situation Documented Symptoms Mandated Action
Accidental Oral Ingestion Dizziness, nausea, vomiting Seek immediate medical attention
Severe Symptoms Trouble breathing, passing out Contact Emergency Services immediately

In the event of accidental oral ingestion, immediate medical assessment is essential, particularly if documented symptoms such as dizziness, nausea, or vomiting are apparent. Regulatory labeling confirms that no specific antidote is known for Clotrimazol intoxication. Therefore, management of an overdose involves strictly symptomatic and supportive treatment.

Procedural measures such as gastric lavage may be conditionally considered in a hospital setting for significant, symptomatic ingestion, provided that the airway can be protected. Population-specific overdose considerations for the elderly or those with underlying conditions are not explicitly documented within the official overdose sections of the topical/vaginal product labels.

Therapeutic Uses of Kamicin

What Kamicin treats: main uses and benefits

Kamicin (Clotrimazol) is commonly used across therapeutic domains where localized fungal mycoses are present. It is generally applied across clinical settings marked by visible infection and significant discomfort, particularly in conditions presenting with localized distress associated with fungal organisms.

Management of Acute Fungal Skin Infections

This therapeutic domain covers conditions characterized by inflammatory or irritative states on the skin, such as Tinea pedis (athlete's foot), Tinea cruris (jock itch), and Tinea corporis (ringworm). Kamicin helps address symptom clusters that may become intense or disruptive, such as pronounced pruritus (itching), burning sensations, or visible skin cracking or redness. It is generally relevant for managing symptoms that interfere with daily comfort and may help with improved day-to-day comfort during symptomatic periods.

Symptomatic Support in Mucosal Yeast Overgrowth

It is also relevant in clinical settings that involve acute or unstable symptom patterns associated with yeast infections, particularly vulvovaginal candidiasis and oropharyngeal candidiasis (thrush). In these situations, the medicine is applied in addressing symptoms related to physical discomfort, such as severe mucosal soreness and burning. Use in this context may assist with improving day-to-day comfort and provides support during difficult episodes by helping ease distress.


Quick Fact: Managing Pruritus and Burning

Kamicin is relevant for easing symptoms related to inflammatory or irritative states, focusing on managing the subjective discomforts of itching and burning associated with fungal infections.

Regulatory References

  1. NIH MedlinePlus overview of Clotrimazole Topical

Eligibility and Restrictions for Use

The official eligibility profile for Kamicin (Clotrimazol) is strictly defined by regulatory documents, outlining populations that are permitted, restricted, or prohibited from using the medicine.

Absolute Contraindication

Use is strictly prohibited in individuals with a known hypersensitivity to the active substance, clotrimazol, or any of the non-medicinal ingredients (excipients) found in the specific cream, solution, or vaginal formulation. This is an absolute regulatory exclusion.

Age Restrictions and Limitations

Topical formulations are generally established for use across age groups, including children, when used as indicated. However, the use of vaginal preparations is typically not recommended for individuals under 16 years of age. Standard use is generally assumed for adults, with no specific restrictions or dose adjustments documented for older adults.

Pregnancy and Lactation

Use during the first trimester of pregnancy is restricted to instances where the clinical need is clearly established. Use in later trimesters is generally permitted with caution. During this period, use of vaginal applicators is restricted. For lactating women, Kamicin should not be applied to the breast area.

Conditional Eligibility

Kamicin is a localized treatment and is not for ophthalmic use. Furthermore, specific forms, such as the otic solution, are not recommended for patients with a perforated tympanic membrane.

What should I know about interactions with other medicines?

Kamicin (Amikacin) interacts with several medicinal products and categories, primarily through increasing the risk of significant toxic effects or enhancing pharmacological actions.

Documented Interaction Categories

Interacting Product Category Interaction Mechanism (Regulatory Statement) Interaction-Related Constraint
Nephrotoxic/Ototoxic Products Additive toxicity (Pharmacodynamic Synergism) Avoid concurrent or sequential use; includes other aminoglycosides, Vancomycin, Cisplatin, Polymyxins (e.g., Colistin), and Amphotericin B.
Potent Diuretics Enhanced toxicity by altering antibiotic concentrations Avoid concurrent use; includes Furosemide and Ethacrynic Acid.
Neuromuscular Blockers Enhanced curare-like effect at the neuromuscular junction Requires close monitoring in certain patients; includes Rocuronium and Succinylcholine.
Live Bacterial Vaccines Pharmacodynamic antagonism Avoid co-administration; wait until antibiotic course is complete.

Administration Requirements

Kamicin should not be physically premixed with other drugs but must be administered separately. Co-administration is especially cautioned in populations with pre-existing renal impairment due to the heightened risk of toxicity, a constraint emphasized in official labeling.

Exposure Alterations

The co-administration of Quinidine can increase the level or effect of Kamicin via its action on the P-glycoprotein efflux transporter, a mechanistic basis stated in official regulatory documentation.

Mechanism of Action

How Kamicin Works: Mechanism of Action

Kamicin exerts its mechanism of action by selectively targeting the bacterial 30S ribosomal subunit and acting as a non-competitive inhibitor of protein synthesis. This structural subunit, which is distinct from human (eukaryotic) ribosomes, is essential for bacterial cell function. Kamicin binds irreversibly to a site on the 16S rRNA of the 30S subunit, which immediately halts the process of protein elongation. The binding also forces the ribosome to misread the mRNA template, causing the incorporation of faulty, non-functional proteins into the bacterial structure.

This mechanistic cascade leads to profound cellular toxicity. The presence of miscoded proteins compromises the physical integrity of the bacterial cell membrane and wall. The subsequent loss of barrier function and control over internal processes causes the rapid and irreversible collapse of the cell's structure, resulting in the demise of the bacterial cells.

Dosage and Administration Information

Kamicin (Clotrimazol) administration is highly specific to the dosage form, following three primary official routes: topical, intravaginal, and oral transmucosal. The medicine is generally prescribed for use in short, consecutive courses, rather than for long-term maintenance regimens.


General Principles of Administration

For dermal applications, the 1% cream or solution is typically applied twice a day to the affected area and surrounding skin. The course is maintained for two to four weeks, although certain conditions like Tinea Pedis may require up to eight weeks. Use in pediatric patients follows the adult regimen for those over three years of age.

Intravaginal use, facilitated by tablets (100 mg, 200 mg, or 500 mg) or cream, follows a fixed-day schedule of one, three, six, or seven consecutive days. Administration is recommended once daily, preferably at bedtime, to maximize contact time. A population-specific instruction notes that insertion for pregnant patients must be performed without the use of an applicator.

Finally, the 10 mg oral lozenge for transmucosal therapy requires a unique schedule of five doses per day, spaced roughly every 3-4 hours. Treatment typically lasts 14 consecutive days, with the lozenge requiring slow dissolution in the mouth over approximately 30 minutes; it is not to be chewed or swallowed whole.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Kamicin

Evidence for use in Mucosal Yeast Overgrowth (Vulvovaginal Candidiasis)

Research has explored Kamicin in conditions characterized by fluctuating or episodic manifestations, such as Vulvovaginal Candidiasis. Studies monitored outcomes related to physical discomfort and functional imbalance, specifically looking for fungal clearance. Studies examined outcomes related to physical discomfort, and the findings describe patterns observed in the measured variables during the study period. For instance, data show patterns related to changes in patient-reported outcomes describing perceived discomfort over defined time intervals. Comparative research examined the medicine against other therapies, and studies monitored how symptoms evolved in the observed populations.

While the available research explores symptom patterns in the short term, certainty remains low when assessing long-term effects, especially regarding recurrence patterns. Follow-up durations were limited in many trials.

Evidence for use in Acute Fungal Skin Infections (Tinea and Cutaneous Candidiasis)

Kamicin was evaluated in conditions associated with acute or disruptive episodes, including Tinea Pedis (athlete's foot) and Tinea Cruris (jock itch). Studies monitored whether outcomes related to physical discomfort (like redness and itching) changed over specific treatment courses. Research was applied in trials assessing short-term symptom patterns. Findings describe patterns observed in the studies, where researchers measured outcomes related to symptom evolution and mycological clearance (fungal clearance confirmed in the lab). Studies explored these effects across various types of fungal species. Comparative evidence is lacking against certain newer topical agents, and there is limited information for long-term outcomes.

What Remains Uncertain in the Research Landscape

The current evidence landscape has gaps that research is ongoing to address. Evidence quality varies across studies, particularly when comparing older trials to modern standards. Data for certain groups, such as those who are elderly or very young, remain insufficient in dedicated trials. Specifically, the published research provides limited data regarding emerging issues such as drug resistance and its potential effects on measured outcomes. Research provides context and describes group patterns, not personal outcomes or predictions.

Frequently Asked Questions (FAQ)

Common questions about Kamicin (FAQ)


Q: How quickly does Kamicin usually start to work?

Clinical documents and official labeling describe that for dermal infections, improvement with relief of itching, known as pruritus, usually occurs within the first week of treatment with the topical solution. The medicine is intended to be used for the full course described in the product information, even if symptoms appear to subside quickly.


Q: How long can a person typically expect to take Kamicin?

The expected treatment duration for Kamicin is highly dependent on the specific dosage form and the type of infection being addressed. Official administration instructions outline various course lengths, ranging from a few days for some vaginal preparations to several weeks for certain topical uses. The total duration is determined by the specific product labeling.


Q: Are there different brand names for the medicine Kamicin?

Yes, the active ingredient clotrimazol, which is Kamicin, is sold under several different trade names globally, depending on the region and the specific formulation (e.g., cream, lozenge, tablet). This is common for medicines with a single active component that have been available for many years.


Q: Can Kamicin be crushed or split if the patient has trouble swallowing?

For the oral lozenge form, official administration instructions specifically state that it should not be chewed or swallowed whole. The lozenge must be allowed to dissolve slowly in the mouth over approximately 30 minutes to ensure proper delivery of the medicine to the affected area.


Q: Can Kamicin make you feel tired or drowsy?

Official documentation does not list tiredness or drowsiness as common side effects. However, the labeling does note the potential for dizziness or confusion, although these are typically seen in the context of rare and serious reactions like a systemic allergic response.


Q: Does Kamicin affect birth control pills?

Official warnings state that vaginal formulations of the medicine may damage latex contraceptive products, such as condoms and diaphragms, making them unreliable. Furthermore, an interaction that may alter the levels of certain types of hormonal contraceptives has also been described in documentation.


Q: What happens if Kamicin is taken with alcohol?

For the oral lozenge form, official warnings may advise limiting or avoiding the use of alcohol. This caution, where it appears in official warnings, is typically related to the possibility of effects on the liver.


Q: Does taking Kamicin require any special monitoring or blood tests?

For the oral lozenge, monitoring of liver function tests is recommended in patients who have pre-existing liver impairment. Additionally, if the patient's symptoms do not improve as expected, official guidance may recommend repeating microbiological studies to confirm the infection diagnosis.


Q: How long does the effect of Kamicin last after the last dose?

For the small amount of clotrimazol that is absorbed into the bloodstream after oral use, the elimination half-life has been described as approximately two hours. This refers to the time it takes for half of the medicine to leave the system. Systemic absorption following topical or vaginal application is minimal.


Q: Can Kamicin be taken with antacids?

Official major interaction documents and warnings do not list any specific contraindications or cautions regarding the concurrent use of clotrimazol and antacids.


Q: What is the overall goal of treatment with Kamicin?

The overall purpose of treatment, as described in clinical documents, is focused on achieving mycological clearance. This refers to the elimination of the fungus and addressing the related physical symptoms.


Q: What should a patient generally expect during the first week of Kamicin treatment?

Clinical documents indicate that for dermal infections, a patient should generally expect to see clinical improvement within the first week of treatment. This improvement often includes the relief of common symptoms like itching and redness.


Q: What are the main findings from the clinical trials of Kamicin?

Main findings from clinical research indicate that both clinical responses (symptom improvement) and mycological responses (fungal clearance) were higher when using the medicine compared to a placebo. Trials noted that adverse events associated with the drug were rare.


Q: Are there any known issues with taking Kamicin long-term?

The medicine is generally prescribed for use in short courses, and not for long-term maintenance. Official research overviews indicate that certainty remains low when assessing long-term effects, as the follow-up periods in many clinical trials were limited.


Q: Are there any specific activities to avoid while on Kamicin, besides driving?

For vaginal formulations, official instructions advise against the use of tampons, douches, spermicides, or other vaginal products during treatment. It is also advised to avoid vaginal intercourse while undergoing treatment with these forms.


Q: What if a person is allergic to ingredients in Kamicin?

Official documents state that the medicine is strictly contraindicated in individuals with a known sensitivity or hypersensitivity to its active component or any of the non-medicinal ingredients. Symptoms of a serious allergic reaction, such as difficulty breathing or swelling, require immediate medical attention.


Q: Why do official documents advise caution when using Kamicin in patients with diabetes?

Official product information notes that frequent vaginal yeast infections may be a sign of a serious underlying medical cause. Such causes can include conditions like diabetes or a weakened immune system, prompting the patient to consult a healthcare provider.

How should Kamicin be stored and disposed of?

The storage and disposal of Kamicin (Clotrimazol) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Requirements

Scope Element Official Regulatory Requirement
Temperature Store at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). Do not freeze.
Protection Keep the product in its original, tightly closed container, protected from excessive heat and moisture.
Safety Keep out of the reach and sight of children.

Disposal Instructions

Unused or expired Kamicin should be disposed of in accordance with local and governmental requirements. Medicines should not be disposed of in the household trash or down the toilet unless specifically instructed by official regulatory guidance. The recommended method is to utilize a drug take-back program or an FDA-recommended household disposal procedure, such as mixing the medicine with an undesirable substance (e.g., used coffee grounds) before sealing and placing it in the trash. Disposal of product into wastewater or sewage systems is restricted.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kamicin found in:

A-Z Index: